6:24 PM
 | 
Dec 20, 2013
 |  BC Extra  |  Company News

Novo seeks EU, U.S. approval for liraglutide for obesity

Novo Nordisk A/S (CSE:NVO; NYSE:NVO) submitted an NDA to FDA and an MAA to EMA for a 3 mg...

Read the full 76 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >